NCT03273387View on ClinicalTrials.gov

The Role of Trimetazidine on Right Ventricle Function in Pulmonary Arterial Hypertension

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 10, 2017

Primary Completion Date

November 1, 2018

Study Completion Date

December 14, 2018

Conditions
Precapillary Pulmonary Hypertension
Interventions
DRUG

Trimetazidine

The participant will received trimetazidine 35 mg bid for 3 months on top of their regular PAH specific therapy.

DRUG

Placebo oral capsule

The participant will received placebo oral capsule bid for 3 months on top of their regular PAH specific therapy.

Trial Locations (1)

11420

National Cardiovascular Center Harapan Kita Hospital, Jakarta

All Listed Sponsors
lead

Indonesia University

OTHER

NCT03273387 - The Role of Trimetazidine on Right Ventricle Function in Pulmonary Arterial Hypertension | Biotech Hunter | Biotech Hunter